Glibenclamide for Brain Contusions: Contextualizing a Promising Clinical Trial Design that Leverages an Imaging-Based...

Area of Science:

• Neuroscience
• Traumatology
• Pharmacology

Background:

• Traumatic brain injury (TBI) presents significant heterogeneity, impeding therapeutic translation.
• Intraparenchymal contusions are a key TBI subtype with high risk of expansion, a major cause of death and disability.
• The sulfonylurea-receptor 1-transient receptor potential melastatin 4 (SUR1-TRPM4) channel is implicated in secondary TBI injury, including contusion progression.

Purpose of the Study:

• To evaluate the safety and efficacy of intravenous glibenclamide (BIIB093) in patients with TBI-related brain contusions.
• To address TBI heterogeneity by focusing on the specific endotype of brain contusion and its expansion.
• To leverage preclinical and early human data supporting SUR1-TRPM4 inhibition for contusion expansion.

Main Methods:

• The ASTRAL trial is an international, multi-center, double-blind, placebo-controlled Phase II clinical trial.
• Enrollment is restricted to patients with the brain contusion pathoanatomic endotype.
• Contusion expansion is utilized as the primary outcome measure.

Main Results:

• Preclinical models show glibenclamide inhibits SUR1-TRPM4, reducing cerebral edema and contusion progression, improving functional outcomes.
• Early human research suggests glibenclamide benefits contusion expansion.
• The ASTRAL trial is actively enrolling 160 participants to further assess glibenclamide's efficacy.

Conclusions:

• Addressing TBI heterogeneity through targeted endotyping (brain contusion) is crucial for therapeutic development.
• SUR1-TRPM4 inhibition represents a promising therapeutic strategy for managing contusion expansion after TBI.
• The ASTRAL trial's design is informed by strong scientific rationale and aims to provide critical data on glibenclamide's role in TBI treatment.